Hemispherx 'Redoubling' US Efforts On Ampligen
Executive Summary
Chronic fatigue drug received two FDA complete response letters, but company now agrees to additional study, new CEO says. Firm hopes Argentine approval also bodes well.
You may also be interested in...
Tech Transfer Roundup: Vanderbilt Teams With Deerfield; Expands Cancer Pact With Boehringer
Vanderbilt launches new biotech with Deerfield aimed at reworking the drug development paradigm, while also expanding its cancer research work with BI. Grunenthal partners with Katholieke Universiteit Leuven to investigate ion channel modulation approaches in pain.
Chronic Fatigue Syndrome Research Takes Leap Forward With NIH Funding
Research centers are collaborating on projects to find causes of disease; Ampligen, Rituxan and KPAX-002 are only drugs in clinical trials.
US FDA draft guideline seeks to foster drug development for chronic fatigue syndrome
The US Food and Drug Administration has released a draft guidance to help drug sponsors develop treatments for chronic fatigue syndrome (CFS), also known as myalgic encephalomyelitis (ME), a condition for which there are currently no FDA-approved medicines1,2.